Latest News
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
18 May 2026 - Biopharmaceutical company AstraZeneca plc (LSE: AZN) (STO: AZN) (NYSE: AZN) reported on Monday that it has received US Food and Drug Administration approval for Baxfendy (baxdrostat), the first and only aldosterone synthase inhibitor fo...
CelLBxHealth partners with AdventHealth on cancer monitoring studies
18 May 2026 - CTC intelligence company CelLBxHealth plc (AIM: CLBX) announced on Monday that it has entered a collaboration with AdventHealth, a US-based faith-based health system, to use its Parsortix platform in two clinical studies focused on mini...
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
18 May 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) disclosed on Monday that Japan's Ministry of Health, Labour and Welfare has expanded approval for its RSV vaccine, Arexvy, to include adults aged 18 to 49 years who are at in...
SciBase research highlights Nevisense potential in age-related skin analysis
18 May 2026 - SciBase Holding AB (STO: SCIB), a developer of AI-based diagnostic solutions for skin disorders, announced on Monday that new research presented at the Society for Investigative Dermatology Annual Meeting showed that its Nevisense platf...
Atisama Therapeutics reports progress in Phase 1 study of RB042
18 May 2026 - Atisama Therapeutics (formerly Rage Bio), an Australian clinical-stage biotechnology company, on Friday reported progress in the Phase 1 study of its lead candidate, RB042.The RB042 Phase 1 study (RB042_1001), evaluating RB042 in health...